Drug Trial Radar · NCT06434792
Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
May 18, 2023
Primary completion
Aug 27, 2024
Study completion Aug 27, 2024
Sponsor
- Lead sponsor
- Hanlim Pharm. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group dose-response phase 2 clinical trial study to evaluate the efficacy and safety of Bronpass Tab. in 96 patients with chronic obstructive pulmonary disease.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Bronpass Tab.Drug
Twice daily for 12 weeks
PlaceboOther
Twice daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in CAT(COPD Assessment Test) total score at Visit 5Time frame: Time frame: 3 months(Visit 5)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Konkuk University School of Medicine
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.